Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma
Dr Christian Blank speaks to cancer about a phase 2 study, known as PRADO, exploring a personalised response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in resectable stage III melanoma patients.
Dr Blank then summarises that neoadjuvant immunotherapy could become a new standard of care for resectable stage III melanoma and explains the next steps
Watch video Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma online without registration, duration hours minute second in high quality. This video was added by user ecancer 15 June 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 74 once and liked it people.